公开(公告)号：DE69907824T2

公开(公告)日：2004-04-15

申请号：DE69907824

申请日：1999-07-12

Applicant: LUCENT TECHNOLOGIES INC ,  ACADEMIA SINICA TAIPEH T AI PE

Inventor： CHUNG PI-YU ,  HUANG YENNUN ,  LIANG DERON ,  SHIH CHIA-YEN ,  YAJNIK SHALINI

IPC: G06F11/00 ,  G06F11/14 ,  G06F11/16 ,  G06F15/177

Abstract: An application module (A) running on a host computer in a computer network is failure-protected with one or more backup copies that are operative on other host computers in the network. In order to effect fault protection, the application module registers itself with a ReplicaManager daemon process (112) by sending a registration message, which message, in addition to identifying the registering application module and the host computer on which it is running, includes the particular replication strategy (cold backup, warm backup, or hot backup) and the degree of replication associated with that application module. The backup copies are then maintained in a fail-over state according to the registered replication strategy. A WatchDog daemon (113), running on the same host computer as the registered application periodically monitors the registered application to detect failures. When a failure, such as a crash or hangup of the application module, is detected, the failure is reported to the ReplicaManager, which effects the requested fail-over actions. An additional backup copy is then made operative in accordance with the registered replication style and the registered degree of replication. A SuperWatchDog daemon process (115-1), running on the same host computer as the ReplicaManager, monitors each host computer in the computer network. When a host failure is detected, each application module running on that host computer is individually failure-protected in accordance with its registered replication style and degree of replication.

公开(公告)号：CA2296052A1

公开(公告)日：2001-08-12

申请号：CA2296052

申请日：2000-02-12

Applicant: ACADEMIA SINICA

Inventor： YU SU-MAY ,  TONG WU-FU

IPC: C12N9/50 ,  C12N15/82 ,  C12N15/29 ,  A01H5/00 ,  C12N5/14

Abstract: The invention relates to a rice cysteine proteinase gene promoter, as well a s vectors, transformed cells; and transgenic plants containing the promoter.

公开(公告)号：NZ507368A

公开(公告)日：2001-06-29

申请号：NZ50736800

申请日：2000-10-05

Applicant: ACADEMIA SINICA INC

Inventor： HSU CHIA-TSE ,  TING CHUN-JEN ,  HWANG JAULANG

IPC: A61K39/00 ,  C07K7/23 ,  C07K14/07 ,  C07K14/21 ,  C12N15/16 ,  C12N15/31 ,  C12N15/39 ,  C07K19/00 ,  C07K14/59 ,  A61K39/104

Abstract: The polypeptide includes a receptor binding domain of a Pseudomonas exotoxin A, and at least two copies of a peptide sequence selected from a gonadotropin releasing hormone and a fragment of a vaccinia virus coat protein. The polypeptide may be used in vaccines.

公开(公告)号：MX388174B

公开(公告)日：2025-03-19

申请号：MX2017013177

申请日：2017-10-12

Applicant: ACADEMIA SINICA

Inventor： CHIU CHIUNG- YI ,  WU HAN- CHUNG ,  LIU I- JU ,  LU RUEI- MIN ,  CHANG YU- LING

IPC: C07K16/28 ,  A61K39/395 ,  A61P35/02 ,  C07K16/22 ,  C07K16/30

Abstract: Se describe un anticuerpo aislado o un fragmento de unión de antígeno del mismo que tiene una afinidad de unión específica aun epitopo localizado dentro del dominio 1 o dominio 3 del receptor del crecimiento endotelial vascular humano 2 (VEGFR2; SEQ ID NO: 74). El epitopo dentro del dominio 3 del VEGFR2 se localiza entre los residuos de aminoácido 250 y 270 de la SEQ ID NO: 74. También se describe el uso del anticuerpo o fragmento de unión de antígeno del mismo en la preparación de un medicamento para inhibir el crecimiento tumoral, angiogénesis tumoral, y/o inducir citotoxicidad en células cancerosas en un sujeto que necesite de lo mismo. También se describe un método para detectar la presencia de VEGFR2 en una célula endotelial tumoral vascular o una célula cancerosa en una muestra biológica.

公开(公告)号：AU2021413867B2

公开(公告)日：2025-02-27

申请号：AU2021413867

申请日：2021-12-30

Applicant: ACADEMIA SINICA

Inventor： CHANG YING-CHIH

IPC: C09D177/04 ,  C08J7/04 ,  C09D129/04 ,  C09D171/02 ,  C12M1/00 ,  C12N5/00

Abstract: The present disclosure provides a surface coating comprising a hydrophilic polymer and polyelectrolyte multilayers. Also provided is a cell culture system comprising a cell culture article having a surface coated with the surface coating. Uses and methods of preparing the surface coatings and systems are provided as well.

公开(公告)号：IL299875B2

公开(公告)日：2024-12-01

申请号：IL29987523

申请日：2023-01-12

Applicant: ACADEMIA SINICA ,  CHI HUEY WONG ,  CHE MA ,  HAN YI HUANG

Inventor： CHI-HUEY WONG ,  CHE MA ,  HAN-YI HUANG

IPC: A61K39/00 ,  A61K39/12 ,  A61K39/15 ,  A61P31/14

Abstract: The present disclosure provides a glycoengineered SARS-CoV-2 spike protein which is capable of eliciting an enhanced immune response relative to a native spike protein of SARS-CoV-2 and its variants. The glycoengineered spike protein exposes the glycosylation sites and at the same time preserves the tertiary structure of the spike protein. The present disclosure therefore provides improved immunogens, vaccines, and methods for better prevention and treatment of the emerging coronavirus infections.

公开(公告)号：AU2021411588A1

公开(公告)日：2022-09-29

申请号：AU2021411588

申请日：2021-12-30

Applicant: ACADEMIA SINICA

Inventor： CHANG YING-CHIH

IPC: C12N5/00 ,  C08J7/12 ,  C09D177/04 ,  G01N33/50

Abstract: The present disclosure provides a substrate for cell culture. Systems comprising the substrate, and methods for using and manufacturing the substrate are also disclosed herein.

公开(公告)号：CA3036690C

公开(公告)日：2022-08-09

申请号：CA3036690

申请日：2017-09-13

Applicant: ACADEMIA SINICA ,  SHEN CHE KUN JAMES ,  SHYU YU CHIAU ,  HUNG CHUN HAO

Inventor： SHEN CHE-KUN JAMES ,  SHYU YU-CHIAU ,  HUNG CHUN-HAO

IPC: A61K38/16 ,  C07K14/47 ,  C12N5/095

Abstract: The invention found that first, the feasibility of transfer of tumor resistance and other healthy longevity characters through transplantation of bone marrow mononuclear cells (BMMNC) or hematopoietic stem cells (HSC)/hematopoietic stem and progenitor cells (HSPC) consisting of genetically engineered EKLF gene encoding the hematopoietic transcription factor EKLF. Secondly, the present invention demonstrates expression of EKLF in the long-term hematopoietic stem cells (LT-HSC), and thus EKLF as a target of regulation of hematopoiesis.

公开(公告)号：IL249186B

公开(公告)日：2022-04-01

申请号：IL24918616

申请日：2016-11-24

Applicant: ACADEMIA SINICA

Abstract: The present disclosure relates to a novel class of anti-CD20 monoclonal antibodies comprising a homogeneous population of anti-CD20 IgG molecules having the same N-glycan on each of Fc. The antibodies of the invention can be produced from anti-CD20 monoclonal antibodies by Fc glycoengineering. Importantly, the antibodies of the invention have improved therapeutic values with increased ADCC activity and increased Fc receptor binding affinity compared to the corresponding monoclonal antibodies that have not been glycoengineered.

公开(公告)号：IL249186A

公开(公告)日：2022-04-01

申请号：IL24918616

申请日：2016-11-24

Applicant: ACADEMIA SINICA

IPC: C07K16/00 ,  A61K39/00 ,  C07K16/28 ,  C12P21/00

Abstract: The present disclosure relates to a novel class of anti-CD20 monoclonal antibodies comprising a homogeneous population of anti-CD20 IgG molecules having the same N-glycan on each of Fc. The antibodies of the invention can be produced from anti-CD20 monoclonal antibodies by Fc glycoengineering. Importantly, the antibodies of the invention have improved therapeutic values with increased ADCC activity and increased Fc receptor binding affinity compared to the corresponding monoclonal antibodies that have not been glycoengineered.